CIITA antibody (N-Term)

Catalog No. ABIN285417

Product Details anti-CIITA Antibody

Target: CIITA (Class II, Major Histocompatibility Complex, Transactivator (CIITA))

Binding Specificity: N-Term

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This CIITA antibody is un-conjugated

Application: Western Blotting (WB), ELISA

Purification: Ion exchange chromatography

Immunogen: Ciita antibody was raised in rabbit using CIITA peptide corresponding to a region near the N-terminus of the human protein conjugated to KLH as the immunogen.

Application Details

Application Notes: ELISA: 1:5,000-1:25,000, WB: 1:500-1:3,000
Optimal conditions should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Concentration: Lot specific

Buffer: Lyophilized from 0.02 M K2 O4, pH 7.2, with 0.12 NaCl and 0.01 % NaN3.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium Azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Handling Advice: Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Storage: -20 °C

Storage Comment: Store at -20 °C. Aliquot and freeze at -20 °C or below for long term storage.

Target Details for CIITA

Target: CIITA (Class II, Major Histocompatibility Complex, Transactivator (CIITA))

Alternative Name: Ciita (CIITA Products)

Synonyms: CIITA antibody, C2ta antibody, EG669998 antibody, Gm9475 antibody, C2TA antibody, CIITAIV antibody, MHC2TA antibody, NLRA antibody, Mhc2ta antibody, class II, major histocompatibility complex, transactivator antibody, class II major histocompatibility complex transactivator antibody, MHC class II transactivator antibody, class II transactivator antibody, CIITA antibody, LOC710761 antibody, ciita antibody, LOC100443575 antibody, Ciita antibody, LOC100736732 antibody

Background: CIITA is a human gene which encodes a protein called the class II, major histocompatibility complex, transactivator. Mutations in this gene are responsible for the bare lymphocyte syndrome in which the immune system is severely compromised and cannot effectively fight infection.

Pathways: Cancer Immune Checkpoints